| Literature DB >> 26703544 |
Tânia C S P Pires1, Maria Inês Dias2, Ricardo C Calhelha3,4, Ana Maria Carvalho5, Maria-João R P Queiroz6, Lillian Barros7, Isabel C F R Ferreira8.
Abstract
Tabebuia impetiginosa (Mart. ex DC.) Standl. has been used in traditional medicine for many centuries, being nowadays marketed as dried plant material (inner bark) for infusions, pills, and syrups. The main objective of the present work was to validate its popular use through the bioactivity evaluation of the inner bark (methanolic extract and infusion) and of two different formulations (pills and syrup) also based on the same plant-material. The antioxidant activity was evaluated by in vitro assays testing free radical scavenging activity, reducing power and inhibition of lipid peroxidation in brain homogenates. The cytotoxicity was determined in four human tumor cell lines (MCF-7, NCI-H460, HeLa and HepG2, and also in non-tumor cells (porcine liver primary cells, PLP2)). Furthermore, the sample was chemically characterized regarding free sugars, organic acids, fatty acids, and tocopherols. Syrup and methanolic extract showed the highest antioxidant activity, related to their highest amount of phenolics and flavonoids. Methanolic extract was the only sample showing cytotoxic effects on the tested human tumor cell lines, but none of the samples showed toxicity in PLP2. Glucose and oxalic acid were, respectively, the most abundant sugar and organic acid in the sample. Unsaturated predominated over the saturated fatty acids, due to oleic, linoleic, and linolenic acids expression. α- and γ-Tocopherols were also identified and quantified. Overall, T. impetiginosa might be used in different phytoformulations, taking advantage of its interesting bioactive properties and chemical composition.Entities:
Keywords: Tabebuia impetiginosa; antioxidants; chemical composition; cytotoxicity; methanolic extract/infusion/dietary supplements
Mesh:
Substances:
Year: 2015 PMID: 26703544 PMCID: PMC6331982 DOI: 10.3390/molecules201219885
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Individual compounds in T. impetigosa inner bark (Mean ± SD).
| Fatty Acids (Relative Percentage) | Free Sugars (g/100 g) | ||
|---|---|---|---|
| C4:0 | 2.31 ± 0.28 | Fructose | 0.25 ± 0.01 |
| C6:0 | 0.99 ± 0.01 | Glucose | 0.53 ± 0.04 |
| C8:0 | 0.79 ± 0.01 | Sucrose | 0.10 ± 0.01 |
| C10:0 | 1.76 ± 0.04 | Total | 0.88 ± 0.04 |
| C12:0 | 1.23 ± 0.03 | ||
| C13:0 | 0.050 ± 0.001 | Oxalic acid | 0.21 ± 0.01 |
| C14:0 | 3.35 ± 0.02 | Malic acid | tr |
| C15:0 | 0.93 ± 0.01 | Citric acid | 0.11 ± 0.02 |
| C16:0 | 17.86 ± 0.16 | Succinic acid | 0.15 ± 0.02 |
| C16:1 | 0.12 ± 0.03 | Fumaric acid | tr |
| C17:0 | 2.28 ± 0.13 | Total | 0.47 ± 0.05 |
| C18:0 | 7.38 ± 0.13 | ||
| C18:1n9 | 32.51 ± 0.32 | α-Tocopherol | 2.07 ± 0.17 |
| C18:2n6 | 11.00 ± 0.02 | γ-Tocopherol | 0.24 ± 0.01 |
| C18:3n3 | 9.40 ± 0.06 | Total | 2.31 ± 0.17 |
| C20:0 | 2.34 ± 0.09 | ||
| C20:1 | 0.87 ± 0.09 | ||
| C20:3n3+C21:0 | 0.45 ± 0.04 | ||
| C22:0 | 1.52 ± 0.14 | ||
| C23:0 | 0.91 ± 0.01 | ||
| C24:0 | 1.97 ± 0.17 | ||
| SFA | 47.68 ± 0.16 | ||
| MUFA | 33.49 ± 0.01 | ||
| PUFA | 18.83 ± 0.18 | ||
The results are expressed in dry weight basis (dw); tr—races. SFA—saturated fatty acids; MUFA—monounsaturated fatty acids; PUFA—polyunsaturated fatty acids; Caproic acid (C6:0); Caprylic acid (C8:0); Capric acid (C10:0); Lauric acid (C12:0); Tridecanoic acid (C13:0); Myristic acid (C14:0); Pentadecanoic acid (C15:0); Palmitic acid (C16:0); Palmitoleic acid (C16:1); Heptadecanoic acid (C17:0); Stearic acid (C18:0); Oleic acid (C18:1n9); Linoleic acid (C18:2n6); α-Linolenic acid (C18:3n3); Arachidic acid (C20:0); Eicosenoic acid (C20:1); cis-11, 14, 17-Eicosatrienoic acid and Heneicosanoic acid (C20:3n3 + C21:0); Behenic acid (C22:0); Tricosylic acid (C23:0); Lignoceric acid (C24:0).
Antioxidant properties of T. impetigosa extracts and dietary supplements (Mean ± SD).
| DPPH scavenging activity | 0.68 ± 0.03 c | 16.68 ± 0.58 a | 5.63 ± 0.19 b | 0.30 ± 0.05 d |
| Reducing power | 0.27 ± 0.01 c | 6.78 ± 0.84 a | 3.45 ± 0.03 b | 0.26 ± 0.01 c |
| β-Carotene bleaching inhibition | 0.23 ± 0.04 c | 10.72 ± 3.53 a | 3.37 ± 0.83 b | 0.26 ± 0.02 c |
| TBARS inhibition | 0.14 ± 0.01 c | 1.87 ± 0.02 a | 1.60 ± 0.02 b | 0.02 ± 0.001 d |
| Phenolics (mg GAE/g extract) | 247.50 ± 8.93 a | 8.11 ± 0.24 d | 14.54 ± 0.90 c | 29.43 ± 0.56 b |
| Flavonoids (mg CE/g extract) | 71.12 ± 4.42 a | 1.67 ± 0.02 d | 4.32 ± 0.13 c | 9.31 ± 0.12 b |
The antioxidant activity was expressed as EC50 values, what means that higher values correspond to lower reducing power or antioxidant potential. EC50: Sample concentration corresponding to 50% of antioxidant activity or 0.5 of absorbance in reducing power assay. Trolox EC50 values: 41 µg/mL (reducing power), 42 µg/mL (DPPH scavenging activity), 18 µg/mL (β-carotene bleaching inhibition) and 23 µg/mL (TBARS inhibition). In each row, different letters mean significant differences between species (p < 0.05).
Cytotoxicity properties of T. impetigosa extracts and dietary supplements (Mean ± SD).
| MCF-7 (breast carcinoma) | 110.76 ± 5.33 | >400 | >400 | >400 |
| NCI-H460 (lung carcinoma) | 76.67 ± 7.09 | >400 | >400 | >400 |
| HeLa (cervical carcinoma) | 93.18 ± 1.46 | >400 | >400 | >400 |
| HepG2 (hepatocellular carcinoma) | 83.61 ± 6.61 | >400 | >400 | >400 |
| PLP2 (porcine liver primary cells) | >400 | >400 | >400 | >400 |
GI50 values correspond to the sample concentration achieving 50% of growth inhibition in human tumor cell lines or in liver primary culture PLP2. Ellipticine GI50 values: 1.21 µg/mL (MCF-7), 1.03 µg/mL (NCI-H460), 0.91 µg/mL (HeLa), 1.10 µg/mL (HepG2) and 2.29 µg/mL (PLP2).